← Back to Screener
DiaMedica Therapeutics Inc. Common Stock (DMAC)
Price$5.64
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-42.57%
Price vs S&P 500 (4W)-10.75%
VGM Score43.39
Market Capitalization$303.90M
All Metrics
Book Value / Share (Quarterly)$0.88
P/TBV (Annual)42.56x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.58
Price vs S&P 500 (YTD)-37.30%
EPS (TTM)$-0.71
10-Day Avg Trading Volume0.15M
EPS Excl Extra (TTM)$-0.71
EPS (Annual)$-0.70
ROI (Annual)-58.38%
Net Profit Margin (5Y Avg)-11188.60%
Cash / Share (Quarterly)$0.95
ROA (Last FY)-53.39%
EBITD / Share (TTM)$-0.74
ROE (5Y Avg)-46.04%
Cash Flow / Share (Annual)$-0.54
P/B Ratio6.43x
P/B Ratio (Quarterly)7.72x
Net Income / Employee (Annual)$-936,200
Net Interest Coverage (TTM)-143.97x
ROA (TTM)-69.18%
EPS Incl Extra (Annual)$-0.70
Current Ratio (Annual)11.81x
Quick Ratio (Quarterly)8.98x
3-Month Avg Trading Volume0.19M
52-Week Price Return37.90%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.38
P/S Ratio (Annual)607.80x
Asset Turnover (Annual)0.03x
52-Week High$10.42
Operating Margin (5Y Avg)-11740.00%
EPS Excl Extra (Annual)$-0.70
CapEx CAGR (5Y)-3.17%
Tangible BV CAGR (5Y)-14.37%
26-Week Price Return-34.65%
Quick Ratio (Annual)11.72x
13-Week Price Return-25.69%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)9.11x
Enterprise Value$299.05M
Book Value / Share Growth (5Y)-5.53%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1130.80%
Cash / Share (Annual)$1.11
3-Month Return Std Dev48.66%
Net Income / Employee (TTM)$-1,002,900
ROE (Last FY)-58.39%
Net Interest Coverage (Annual)-49.10x
EPS Basic Excl Extra (Annual)$-0.70
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.71
Receivables Turnover (Annual)1.16x
ROI (TTM)-77.06%
Pretax Margin (5Y Avg)-11149.80%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.38
Price vs S&P 500 (52W)13.53%
Year-to-Date Return-29.15%
5-Day Price Return-3.42%
EPS Normalized (Annual)$-0.70
ROA (5Y Avg)-42.30%
Net Profit Margin (Annual)-1146.80%
Month-to-Date Return-5.84%
Cash Flow / Share (TTM)$-0.61
EBITD / Share (Annual)$-0.73
Operating Margin (Annual)-1352.20%
LT Debt / Equity (Annual)0.01x
ROI (5Y Avg)-46.03%
LT Debt / Equity (Quarterly)0.01x
EPS Basic Excl Extra (TTM)$-0.71
P/TBV (Quarterly)42.56x
P/B Ratio (Annual)7.39x
Book Value / Share (Annual)$1.04
Price vs S&P 500 (13W)-33.95%
Beta1.05x
Revenue / Share (TTM)$0.00
ROE (TTM)-77.09%
52-Week Low$3.48
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.19est. -0.19
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.09
4.09
4.09
4.09
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
DMACDiaMedica Therapeutics Inc. Common Stock | — | — | C | $5.64 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company developing therapies for ischemic diseases and acute pancreatitis. Its lead candidate, DM199, a recombinant human enzyme, is in clinical trials for acute ischemic stroke and preeclampsia. The company also develops DM300, a protease inhibitor being evaluated for severe acute pancreatitis.